These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32393215)

  • 21. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD.
    Donohue JF; Mahler DA; Sethi S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2947-2958. PubMed ID: 31908443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
    Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
    Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses.
    Iqbal A; Barnes NC; Brooks J
    Clin Drug Investig; 2015 Oct; 35(10):685-8. PubMed ID: 26329916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.
    Ferguson GT; Feldman G; Pudi KK; Barnes CN; Moran EJ; Haumann B; Pendyala S; Crater G
    Chronic Obstr Pulm Dis; 2019 Apr; 6(2):154-165. PubMed ID: 30974049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
    Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
    Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
    Donohue JF; Jones PW; Bartels C; Marvel J; D'Andrea P; Banerji D; Morris DG; Patalano F; Fogel R
    Pulm Pharmacol Ther; 2018 Apr; 49():11-19. PubMed ID: 29277690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
    Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
    Fukushima Y; Nakatani Y; Ide Y; Sekino H; St Rose E; Siddiqui S; Maes A; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1187-1194. PubMed ID: 29695902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
    Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
    Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
    Kerwin EM; Murray L; Niu X; Dembek C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y; Kinoshita M; Lee SH; Hang LW; Ichinose M; Fukuchi Y; Kitawaki T; Okino N; Prasad N; Lawrence D; Kramer B
    Respir Med; 2012 Dec; 106(12):1715-21. PubMed ID: 23040786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression.
    Yohannes AM; Iyer AS; Clay C; Cochran L; Chen X; Lombardi DA; Bhatt SP
    Chronic Obstr Pulm Dis; 2024 Mar; 11(2):196-205. PubMed ID: 38241514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
    Calverley PMA; Hoz A; Xue W; Ferguson GT; Miravitlles M
    COPD; 2020 Oct; 17(5):477-484. PubMed ID: 32928003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.